Jürgen Bulitta

Jürgen Bulitta, Ph.D.

Professor

Department: Pharmacotherapy & Translational Research
Business Phone: (407) 313-7010
Business Email: jbulitta@cop.ufl.edu

About Jürgen Bulitta

Jürgen B. Bulitta, PhD, is a professor in the Department of Pharmacotherapy and Translational Research at the UF College of Pharmacy. He is supported by the University of Florida’s preeminence program in Drug Discovery and Development, and received the Perry E. Foote Eminent Scholar Chair, Endowed Professorship, in 2019. Dr. Bulitta’s research focuses on combating multidrug-resistant bacterial ‘superbugs’ which present one of the three most serious threats to human health.

His mission is to optimize patient therapies and innovative drug development by providing a focal point for translational research in infectious diseases and related areas, and to serve as an internationally-leading, interdisciplinary, collaborative program for translational research.

Dr. Bulitta’s vision is to provide novel solutions and great hope for patients with serious, life-threatening infections by developing new safe and effective therapies. These are informed at the molecular level by an innovative combination of mechanistic, in vitro, animal and quantitative approaches to rationally optimize outcomes in patients. His highly collaborative research program leverages latest pharmacological, microbiological, biochemical and computational approaches. This creates unique translational insights that enable novel therapies and dosing strategies, as well as the design and development of new drugs. We work hard so that we can say “we have an effective therapy for you” when you most need it.

He won 26 peer-reviewed grants (15 as PI) from the NIH, FDA, the Australian equivalents of NIH and NSF, as well as 30 collaborative projects with pharmaceutical industry (total: $35M, 18M active). Dr. Bulitta published 140 peer-reviewed papers and contributed to over 97 phase I-IV clinical trials. He reviewed for several NIH study sections and received 23 awards since 1998. These include the Giorgio Segré Prize 2010 for distinct contributions in the field of pharmacokinetics and pharmacodynamics by the European Federation for Pharmaceutical Sciences (EUFEPS) and the 2012 ASCEPT Denis Wade Johnson & Johnson New Investigators Award. Dr. Bulitta created the Translational Clinical Pharmacology course (PHA6133). He is the creator and developed of the SADAPT-TRAN package that greatly facilitates the development of systems pharmacology models in the S-ADAPT population modeling package.

Accomplishments

Reviewer for Drug Discovery and Mechanisms of Antimicrobial Resistance [DDR] Study Section
2017 · NIH/NIAID
Teaching and Service Excellence Incentive Award
2017 · UF College of Pharmacy
Career Development Fellow Level II
2014 · Australian National Health and Medical Research Council
ASCEPT Denis Wade Johnson & Johnson New Investigators Award
2012 · The Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT)
Discovery Early Career Researcher Award and 3-year Fellowship
2011 · Australian Research Council
Giorgio Segré Prize 2010 for distinct contributions in the field of pharmacokinetics and pharmacodynamics
2011 · European Federation for Pharmaceutical Sciences
Editorial Board Member
2009 · Antimicrobial Agents and Chemotherapy
Best UB fellow research presentation
2008 · SUNY Buffalo
Outstanding Modeling and Simulation Abstract Award
2008 · American Conference on Pharmacometrics
Best Fellow Presentation at the post-ICAAC meeting
2007 · International Society of Anti-Infective Pharmacology
Best PhD thesis prize in 2006/07
2007 · The Institute of Chemistry and Pharmacy at the Julius-Maximilians University of Würzburg, Germany
Best UB fellow research presentation
2007 · SUNY Buffalo
Award for student participation
2006 · 56th Meeting of Nobel Laureates in Lindau, Germany
Fastest studies in chemistry since more than a decade
2003 · Friedrich-Alexander University, Erlangen-Nürnberg, Germany
Scholarship
2002 · German National Academic Foundation
Best secondary school qualification and best qualification in chemistry
1998 · Primary School and Lyceum, Scheinfeld, Bavaria, Germany
First prize in chemistry (regional competition): “PKPD modeling: Selection of resistant mutants of Staphylococcus epidermidis due to quinolone exposure in sweat“
1998 · “Jugend forscht” (Junior Scientific Competition in Germany)
Invited “Young Scientist” speaker at the “90-years anniversary of the Nobel-Prize honoring to Paul Ehrlich”
1998 · The Paul-Ehrlich Society; Frankfurt, Germany
Scholarship (4-yr)
1998 · State of Bavaria, Germany

Research Profile

Dr. Bulitta’s research focuses on multidrug-resistant bacterial ‘superbugs’ which present one of the three most serious threats to human health. His research goals are to develop and rationally optimize novel antibiotic combination dosing strategies and to discover and develop new antibiotics based on mechanistic biological insights which his group generated. Dr. Bulitta’s research focuses on Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli. His group is systematically identifying unique penicillin-binding protein (PBP) receptor occupancy patterns using double beta-lactam antibiotic combinations to synergistically kill these ‘superbugs’. Moreover, Dr. Bulitta is developing novel strategies to eradicate non-replicating bacterial persisters via available antibiotics and has pioneered the field of mechanism-based and Quantitative and Systems Pharmacology modeling of antibiotics. Dr. Bulitta’s group leverages latest dynamic in vitro infection models, biochemical and molecular studies, LC-MS/MS bioanalysis, as well as latest pharmacometrics methodology to develop and rationally optimize efficacious antibiotic combinations. His highly collaborative research involves an international network of academic, clinical and industry scientists. Dr. Bulitta is collaborating with experts in animal infection models, antibiotic drug development, bacterial resistance mechanisms and genetics, transcriptomics, proteomics, metabolomics, lipidomics, medicinal chemistry, flow cytometry, advanced imaging techniques, and clinical infectious diseases.

Areas of Interest
  • Acinetobacter baumannii
  • Aminoglycosides
  • Antibiotics
  • Beta-lactamase inhibitors
  • Beta-lactams
  • Eradication of non-replicating bacterial persisters
  • Escherichia coli
  • Klebsiella pneumoniae
  • Mechanism-based mathematical modeling
  • Mechanisms of antibiotic action and synergy
  • Multidrug-resistant bacterial ‘superbugs’ and their resistance mechanisms
  • Omics techniques and single cell analyses
  • Penicillin-binding protein (PBP) occupancy patterns
  • Pharmacodynamics
  • Polymyxins
  • Population pharmacokinetics
  • Pseudomonas aeruginosa
  • Quantitative and Systems Pharmacology modeling
  • Rationally optimizing anti-infective combination dosing strategies
  • Staphylococcus aureus
  • Toxicodynamics
  • Translational drug development

Publications

2021
Can Pharmacokinetic Studies Assess the Pulmonary Fate of Dry Powder Inhaler Formulations of Fluticasone Propionate?
The AAPS journal. 23(3) [DOI] 10.1208/s12248-021-00569-x. [PMID] 33768368.
2021
Combating Multidrug-Resistant Bacteria by Integrating a Novel Target Site Penetration and Receptor Binding Assay Platform Into Translational Modeling.
Clinical pharmacology and therapeutics. 109(4):1000-1020 [DOI] 10.1002/cpt.2205. [PMID] 33576025.
2020
First Penicillin-Binding Protein Occupancy Patterns for 15 β-Lactams and β-Lactamase Inhibitors in Mycobacterium abscessus.
Antimicrobial agents and chemotherapy. 65(1) [DOI] 10.1128/AAC.01956-20. [PMID] 33106266.
2020
Novel Cassette Assay To Quantify the Outer Membrane Permeability of Five β-Lactams Simultaneously in Carbapenem-Resistant Klebsiella pneumoniae and Enterobacter cloacae.
mBio. 11(1) [DOI] 10.1128/mBio.03189-19. [PMID] 32047131.
2019
Cascade Impactor Equivalence Testing: Comparison of the Performance of the Modified Chi-Square Ratio Statistic (mCSRS) with the Original CSRS and EMA’s Average Bioequivalence Approach.
AAPS PharmSciTech. 20(6) [DOI] 10.1208/s12249-019-1443-7. [PMID] 31286316.
2019
Comparable Bioavailability and Disposition of Pefloxacin in Patients with Cystic Fibrosis and Healthy Volunteers Assessed via Population Pharmacokinetics.
Pharmaceutics. 11(7) [DOI] 10.3390/pharmaceutics11070323. [PMID] 31295857.
2019
Comparable Efficacy and Better Safety of Double β-Lactam Combination Therapy versus β‑Lactam plus Aminoglycoside in Gram-Negative Bacteria in Randomized, Controlled Trials.
Antimicrobial agents and chemotherapy. 63(7) [DOI] 10.1128/AAC.00425-19. [PMID] 30988147.
2019
Four Decades of β-Lactam Antibiotic Pharmacokinetics in Cystic Fibrosis.
Clinical pharmacokinetics. 58(2):143-156 [DOI] 10.1007/s40262-018-0678-x. [PMID] 29936678.
2019
Generating Robust and Informative Nonclinical In Vitro and In Vivo Bacterial Infection Model Efficacy Data To Support Translation to Humans.
Antimicrobial agents and chemotherapy. 63(5) [DOI] 10.1128/AAC.02307-18. [PMID] 30833428.
2018
Clinical Regimens of Favipiravir Inhibit Zika Virus Replication in the Hollow-Fiber Infection Model.
Antimicrobial agents and chemotherapy. 62(9) [DOI] 10.1128/AAC.00967-18. [PMID] 29967017.
2018
Combating Carbapenem-Resistant Acinetobacter baumannii by an Optimized Imipenem-plus-Tobramycin Dosage Regimen: Prospective Validation via Hollow-Fiber Infection and Mathematical Modeling.
Antimicrobial agents and chemotherapy. 62(4) [DOI] 10.1128/AAC.02053-17. [PMID] 29339388.
2018
First population pharmacokinetic analysis showing increased quinolone metabolite formation and clearance in patients with cystic fibrosis compared to healthy volunteers.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 123:416-428 [DOI] 10.1016/j.ejps.2018.07.054. [PMID] 30076955.
2018
Optimization of a Meropenem-Tobramycin Combination Dosage Regimen against Hypermutable and Nonhypermutable Pseudomonas aeruginosa via Mechanism-Based Modeling and the Hollow-Fiber Infection Model.
Antimicrobial agents and chemotherapy. 62(4) [DOI] 10.1128/AAC.02055-17. [PMID] 29437610.
2018
Zika Virus Replication Is Substantially Inhibited by Novel Favipiravir and Interferon Alpha Combination Regimens.
Antimicrobial agents and chemotherapy. 62(1) [DOI] 10.1128/AAC.01983-17. [PMID] 29109164.
2017
Aminoglycoside Concentrations Required for Synergy with Carbapenems against Pseudomonas aeruginosa Determined via Mechanistic Studies and Modeling.
Antimicrobial agents and chemotherapy. 61(12) [DOI] 10.1128/AAC.00722-17. [PMID] 28893782.
2017
Aminoglycosides against carbapenem-resistant Enterobacteriaceae in the critically ill: the pitfalls of aminoglycoside susceptibility.
Expert review of anti-infective therapy. 15(6):519-526 [DOI] 10.1080/14787210.2017.1316193. [PMID] 28375030.
2017
Characterizing the time-course of antihypertensive activity and optimal dose range of fimasartan via mechanism-based population modeling.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 107:32-44 [DOI] 10.1016/j.ejps.2017.06.008. [PMID] 28599987.
2017
Development of an Enantioselective and Biomarker-Informed Translational Population Pharmacokinetic/Pharmacodynamic Model for Etodolac.
The AAPS journal. 19(6):1814-1825 [DOI] 10.1208/s12248-017-0138-9. [PMID] 28875479.
2017
Evaluation of Pharmacokinetic/Pharmacodynamic Model-Based Optimized Combination Regimens against Multidrug-Resistant Pseudomonas aeruginosa in a Murine Thigh Infection Model by Using Humanized Dosing Schemes.
Antimicrobial agents and chemotherapy. 61(12) [DOI] 10.1128/AAC.01268-17. [PMID] 28993331.
2017
High-intensity meropenem combinations with polymyxin B: new strategies to overcome carbapenem resistance in Acinetobacter baumannii.
The Journal of antimicrobial chemotherapy. 72(1):153-165 [PMID] 27634916.
View on: PubMed
2017
Optimization of Synergistic Combination Regimens against Carbapenem- and Aminoglycoside-Resistant Clinical Pseudomonas aeruginosa Isolates via Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling.
Antimicrobial agents and chemotherapy. 61(1) [DOI] 10.1128/AAC.01011-16. [PMID] 27821448.
2017
Population Pharmacokinetics and Target Attainment of Ertapenem in Plasma and Tissue Assessed via Microdialysis in Morbidly Obese Patients after Laparoscopic Visceral Surgery.
Antimicrobial agents and chemotherapy. 61(1) [DOI] 10.1128/AAC.00952-16. [PMID] 27795367.
2016
Colistin and Polymyxin B Dosage Regimens against Acinetobacter baumannii: Differences in Activity and the Emergence of Resistance.
Antimicrobial agents and chemotherapy. 60(7):3921-33 [DOI] 10.1128/AAC.02927-15. [PMID] 27067324.
2016
Distinguishing Antimicrobial Models with Different Resistance Mechanisms via Population Pharmacodynamic Modeling.
PLoS computational biology. 12(3) [DOI] 10.1371/journal.pcbi.1004782. [PMID] 26967893.
2016
Resistance suppression by high-intensity, short-duration aminoglycoside exposure against hypermutable and non-hypermutable Pseudomonas aeruginosa.
The Journal of antimicrobial chemotherapy. 71(11):3157-3167 [PMID] 27521357.
View on: PubMed
2015
Colistin and doripenem combinations against Pseudomonas aeruginosa: profiling the time course of synergistic killing and prevention of resistance.
The Journal of antimicrobial chemotherapy. 70(5):1434-42 [DOI] 10.1093/jac/dku567. [PMID] 25712313.
2015
Novel approach to optimize synergistic carbapenem-aminoglycoside combinations against carbapenem-resistant Acinetobacter baumannii.
Antimicrobial agents and chemotherapy. 59(4):2286-98 [DOI] 10.1128/AAC.04379-14. [PMID] 25645842.
2015
PEGylation does not significantly change the initial intravenous or subcutaneous pharmacokinetics or lymphatic exposure of trastuzumab in rats but increases plasma clearance after subcutaneous administration.
Molecular pharmaceutics. 12(3):794-809 [DOI] 10.1021/mp5006189. [PMID] 25644368.
2015
Polymyxin combinations: pharmacokinetics and pharmacodynamics for rationale use.
Pharmacotherapy. 35(1):34-42 [DOI] 10.1002/phar.1537. [PMID] 25630411.
2015
Population data analysis of dissolution time profiles: Assessment of physicochemical properties of the drug, drug particles and the pharmaceutical formulation.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 78:245-54 [DOI] 10.1016/j.ejps.2015.07.017. [PMID] 26215465.
2015
Population Pharmacokinetic Modeling of the Enterohepatic Recirculation of Fimasartan in Rats, Dogs, and Humans.
The AAPS journal. 17(5):1210-23 [DOI] 10.1208/s12248-015-9764-2. [PMID] 25990964.
2015
Shape does matter: short high-concentration exposure minimizes resistance emergence for fluoroquinolones in Pseudomonas aeruginosa.
The Journal of antimicrobial chemotherapy. 70(3):818-26 [DOI] 10.1093/jac/dku437. [PMID] 25381167.
2015
Two mechanisms of killing of Pseudomonas aeruginosa by tobramycin assessed at multiple inocula via mechanism-based modeling.
Antimicrobial agents and chemotherapy. 59(4):2315-27 [DOI] 10.1128/AAC.04099-14. [PMID] 25645838.
2014
Clinical population pharmacokinetics and toxicodynamics of linezolid.
Antimicrobial agents and chemotherapy. 58(4):2334-43 [DOI] 10.1128/AAC.01885-13. [PMID] 24514086.
2014
Doripenem population pharmacokinetics and dosing requirements for critically ill patients receiving continuous venovenous haemodiafiltration.
The Journal of antimicrobial chemotherapy. 69(9):2508-16 [DOI] 10.1093/jac/dku177. [PMID] 24879665.
2014
Evaluation of enrofloxacin use in koalas (Phascolarctos cinereus) via population pharmacokinetics and Monte Carlo simulation.
Journal of veterinary pharmacology and therapeutics. 37(3):301-11 [DOI] 10.1111/jvp.12091. [PMID] 24219009.
2013
Combination therapy for carbapenem-resistant Gram-negative bacteria.
Expert review of anti-infective therapy. 11(12):1333-53 [DOI] 10.1586/14787210.2013.845523. [PMID] 24191943.
2013
Mechanism-based model of parasite growth and dihydroartemisinin pharmacodynamics in murine malaria.
Antimicrobial agents and chemotherapy. 57(1):508-16 [DOI] 10.1128/AAC.01463-12. [PMID] 23147722.
2013
PEGylated polylysine dendrimers increase lymphatic exposure to doxorubicin when compared to PEGylated liposomal and solution formulations of doxorubicin.
Journal of controlled release : official journal of the Controlled Release Society. 172(1):128-136 [DOI] 10.1016/j.jconrel.2013.08.004. [PMID] 23954628.
2013
Population pharmacokinetics of fusidic acid: rationale for front-loaded dosing regimens due to autoinhibition of clearance.
Antimicrobial agents and chemotherapy. 57(1):498-507 [DOI] 10.1128/AAC.01354-12. [PMID] 23147726.
2013
Quantifying subpopulation synergy for antibiotic combinations via mechanism-based modeling and a sequential dosing design.
Antimicrobial agents and chemotherapy. 57(5):2343-51 [DOI] 10.1128/AAC.00092-13. [PMID] 23478962.
2012
Evaluation of once-daily vancomycin against methicillin-resistant Staphylococcus aureus in a hollow-fiber infection model.
Antimicrobial agents and chemotherapy. 56(2):682-6 [DOI] 10.1128/AAC.05664-11. [PMID] 22083484.
2012
Front-loaded linezolid regimens result in increased killing and suppression of the accessory gene regulator system of Staphylococcus aureus.
Antimicrobial agents and chemotherapy. 56(7):3712-9 [DOI] 10.1128/AAC.05453-11. [PMID] 22526313.
2012
Pharmacodynamics of early, high-dose linezolid against vancomycin-resistant enterococci with elevated MICs and pre-existing genetic mutations.
The Journal of antimicrobial chemotherapy. 67(9):2182-90 [DOI] 10.1093/jac/dks201. [PMID] 22685161.
2012
Population pharmacokinetics of piperacillin at two dose levels: influence of nonlinear pharmacokinetics on the pharmacodynamic profile.
Antimicrobial agents and chemotherapy. 56(11):5715-23 [DOI] 10.1128/AAC.00937-12. [PMID] 22908169.
2012
Powder strength distributions for understanding de-agglomeration of lactose powders.
Pharmaceutical research. 29(10):2926-35 [DOI] 10.1007/s11095-012-0799-0. [PMID] 22695732.
2012
Resistance emergence mechanism and mechanism of resistance suppression by tobramycin for cefepime for Pseudomonas aeruginosa.
Antimicrobial agents and chemotherapy. 56(1):231-42 [DOI] 10.1128/AAC.05252-11. [PMID] 22005996.
2011
Application of pharmacokinetic-pharmacodynamic modeling and the justification of a novel fusidic acid dosing regimen: raising Lazarus from the dead.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 52 Suppl 7:S513-9 [DOI] 10.1093/cid/cir166. [PMID] 21546628.
2011
Clinically relevant plasma concentrations of colistin in combination with imipenem enhance pharmacodynamic activity against multidrug-resistant Pseudomonas aeruginosa at multiple inocula.
Antimicrobial agents and chemotherapy. 55(11):5134-42 [DOI] 10.1128/AAC.05028-11. [PMID] 21876058.
2011
Comparable population pharmacokinetics and pharmacodynamic breakpoints of cefpirome in cystic fibrosis patients and healthy volunteers.
Antimicrobial agents and chemotherapy. 55(6):2927-36 [DOI] 10.1128/AAC.01484-10. [PMID] 21402834.
2011
Development of a new pre- and post-processing tool (SADAPT-TRAN) for nonlinear mixed-effects modeling in S-ADAPT.
The AAPS journal. 13(2):201-11 [DOI] 10.1208/s12248-011-9257-x. [PMID] 21369876.
2011
Effect of half-life on the pharmacodynamic index of zanamivir against influenza virus delineated by a mathematical model.
Antimicrobial agents and chemotherapy. 55(4):1747-53 [DOI] 10.1128/AAC.01629-10. [PMID] 21263045.
2011
Performance and robustness of the Monte Carlo importance sampling algorithm using parallelized S-ADAPT for basic and complex mechanistic models.
The AAPS journal. 13(2):212-26 [DOI] 10.1208/s12248-011-9258-9. [PMID] 21374103.
2011
Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections.
Antimicrobial agents and chemotherapy. 55(2):583-92 [DOI] 10.1128/AAC.00076-10. [PMID] 21115795.
2011
Population pharmacokinetics and penetration into prostatic, seminal, and vaginal fluid for ciprofloxacin, levofloxacin, and their combination.
Chemotherapy. 57(5):402-16 [DOI] 10.1159/000329520. [PMID] 22024700.
2011
Relevance of pharmacokinetic and pharmacodynamic modeling to clinical care of critically ill patients.
Current pharmaceutical biotechnology. 12(12):2044-61 [PMID] 21554212.
View on: PubMed
2011
Synergistic killing of multidrug-resistant Pseudomonas aeruginosa at multiple inocula by colistin combined with doripenem in an in vitro pharmacokinetic/pharmacodynamic model.
Antimicrobial agents and chemotherapy. 55(12):5685-95 [DOI] 10.1128/AAC.05298-11. [PMID] 21911563.
2010
Attenuation of colistin bactericidal activity by high inoculum of Pseudomonas aeruginosa characterized by a new mechanism-based population pharmacodynamic model.
Antimicrobial agents and chemotherapy. 54(5):2051-62 [DOI] 10.1128/AAC.00881-09. [PMID] 20211900.
2010
Nonlinear pharmacokinetics of piperacillin in healthy volunteers–implications for optimal dosage regimens.
British journal of clinical pharmacology. 70(5):682-93 [DOI] 10.1111/j.1365-2125.2010.03750.x. [PMID] 21039762.
2010
Pharmacokinetic/pharmacodynamic investigation of colistin against Pseudomonas aeruginosa using an in vitro model.
Antimicrobial agents and chemotherapy. 54(9):3783-9 [DOI] 10.1128/AAC.00903-09. [PMID] 20585118.
2009
Comparison of the pharmacokinetics and pharmacodynamic profile of carumonam in cystic fibrosis patients and healthy volunteers.
Diagnostic microbiology and infectious disease. 65(2):130-41 [DOI] 10.1016/j.diagmicrobio.2009.06.018. [PMID] 19748423.
2009
Development and qualification of a pharmacodynamic model for the pronounced inoculum effect of ceftazidime against Pseudomonas aeruginosa.
Antimicrobial agents and chemotherapy. 53(1):46-56 [DOI] 10.1128/AAC.00489-08. [PMID] 18852268.
2009
Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients.
Cancer chemotherapy and pharmacology. 63(6):1049-63 [DOI] 10.1007/s00280-008-0827-2. [PMID] 18791718.
2009
Multiple-pool cell lifespan models for neutropenia to assess the population pharmacodynamics of unbound paclitaxel from two formulations in cancer patients.
Cancer chemotherapy and pharmacology. 63(6):1035-48 [DOI] 10.1007/s00280-008-0828-1. [PMID] 18791717.
2009
New semiphysiological absorption model to assess the pharmacodynamic profile of cefuroxime axetil using nonparametric and parametric population pharmacokinetics.
Antimicrobial agents and chemotherapy. 53(8):3462-71 [DOI] 10.1128/AAC.00054-09. [PMID] 19528278.
2009
Penetration of antibacterials into bone: pharmacokinetic, pharmacodynamic and bioanalytical considerations.
Clinical pharmacokinetics. 48(2):89-124 [DOI] 10.2165/0003088-200948020-00002. [PMID] 19271782.
2009
Pharmacodynamics of vancomycin at simulated epithelial lining fluid concentrations against methicillin-resistant Staphylococcus aureus (MRSA): implications for dosing in MRSA pneumonia.
Antimicrobial agents and chemotherapy. 53(9):3894-901 [DOI] 10.1128/AAC.01585-08. [PMID] 19596879.
2008
Pharmacokinetics of 1,4-butanediol in rats: bioactivation to gamma-hydroxybutyric acid, interaction with ethanol, and oral bioavailability.
The AAPS journal. 10(1):56-69 [DOI] 10.1208/s12248-007-9006-3. [PMID] 18446506.
2007
Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial.
Antimicrobial agents and chemotherapy. 51(9):3304-10 [PMID] 17620371.
View on: PubMed
2007
Population pharmacokinetics at two dose levels and pharmacodynamic profiling of flucloxacillin.
Antimicrobial agents and chemotherapy. 51(9):3290-7 [PMID] 17576847.
View on: PubMed
2007
Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers.
Antimicrobial agents and chemotherapy. 51(7):2497-507 [PMID] 17485505.
View on: PubMed
2006
Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units.
The Journal of antimicrobial chemotherapy. 58(5):987-93 [PMID] 16943209.
View on: PubMed
2005
Evaluation by monte carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers.
Antimicrobial agents and chemotherapy. 49(5):1881-9 [PMID] 15855510.
View on: PubMed
2004
Ertapenem pharmacokinetics and impact on intestinal microflora, in comparison to those of ceftriaxone, after multiple dosing in male and female volunteers.
Antimicrobial agents and chemotherapy. 48(10):3765-72 [PMID] 15388432.
View on: PubMed
2002
Effects of grapefruit juice on the pharmacokinetics of sildenafil.
Clinical pharmacology and therapeutics. 71(1):21-9 [PMID] 11823754.
View on: PubMed
1999
Interaction of pefloxacin and enoxacin with the human cytochrome P450 enzyme CYP1A2.
Clinical pharmacology and therapeutics. 65(3):262-74 [PMID] 10096258.
View on: PubMed

Grants

Dec 2020 ACTIVE
Mechanistically optimized antibiotic combinations to combat resistant Klebsiella pneumoniae
Role: Other
Funding: AMER COL OF CLINICAL PHAR
Dec 2019 ACTIVE
Novel Strategies for Antibiotic Combinations to Combat Gram-negative Superbugs
Role: Principal Investigator
Funding: STATE UNIV OF NEW YORK BUFFALO via NATL INST OF HLTH NIAID
Sep 2019 ACTIVE
Systematic evaluation of the ex-throat plume properties of MDI formulations
Role: Principal Investigator
Funding: US FOOD AND DRUG ADMN
Feb 2019 – Sep 2019
New Strain Testing and PK-PD Studies for Therapeutics in Murine Models of Bacterial Thigh Infections
Role: Principal Investigator
Funding: PHARMACOLOGY DISCOVERY SERVICES TAIWAN via NATL INST OF HLTH NIAID
Feb 2019 – Dec 2019
Mathematical modeling of antimicrobial resistance
Role: Principal Investigator
Funding: STATE UNIV OF NEW YORK BUFFALO via NATL INST OF HLTH NIAID
Aug 2018 ACTIVE
Combating resistant superbugs by understanding the molecular determinants of target site penetration and binding
Role: Principal Investigator
Funding: NATL INST OF HLTH NIAID
Nov 2017 ACTIVE
Next-generation combination dosing strategies to combat resistant Acinetobacter baumannii
Role: Principal Investigator
Funding: NATL INST OF HLTH NIAID
Sep 2017 ACTIVE
A Preclinical Mouse Model of Acinetobacter buamannii Infection For Antibacterial Development
Role: Principal Investigator
Funding: UNIV OF SOUTHERN CALIFORNIA via US FOOD AND DRUG ADMN
Jun 2017 – May 2021
OR-DRPD-ROF2017:Combating resistant Gram-negative bacterial superbugs via omics techniques
Role: Principal Investigator
Funding: UF DSR OPPORTUNITY FUND
Apr 2017 – Jun 2021
OoR CTSI Institutional Matching Support
Role: Project Manager
Funding: UF DIV OF SPONSORED RES MATCHING FUNDS
Mar 2017 – Jun 2018
Identification of antiviral therapies for the treatment of Zika virus using existing drugs
Role: Co-Investigator
Funding: FL DEPT OF HLTH
Mar 2017 – May 2017
Pharmacokinetic optimization of the platelet aggregation inhibitor ticagrelor
Role: Principal Investigator
Funding: INDUSTRY ACADEMIC COOPERATION FOU
Mar 2017 – May 2017
Supporting the rational development of a generic dutasteride formulation by pharmacokinetic data analyses and simulations
Role: Principal Investigator
Funding: INDUSTRY ACADEMIC COOPERATION FOU
Sep 2016 – Mar 2018
Pharmacokinetic Comparison of Locally Acting Orally Inhaled Drug Products
Role: Principal Investigator
Funding: US FOOD AND DRUG ADMN
Aug 2015 – Mar 2019
Novel PK/PD Strategies for Polymyxin Combinations against Gram-negative Superbugs
Role: Principal Investigator
Funding: STATE UNIV OF NEW YORK BUFFALO via NATL INST OF HLTH NIAID
Dec 2014 – Feb 2020
Comprehensive Evaluation of Formulation Effects on Metered Dose Inhaler Performance
Role: Co-Investigator
Funding: US FOOD AND DRUG ADMN
Sep 2013 – Apr 2020
Study to Investigate the Sensitivity of Pharmacokinetics in Detecting Differences in Physicochemical Properties of the Active in Suspension Nasal Products for Local Action
Role: Principal Investigator
Funding: US FOOD AND DRUG ADMN

Education

Postdoc – Pharmaceutical sciences
2009 · University at Buffalo SUNY, Buffalo, NY, USA
Ph.D. – Pharmaceutical sciences / chemistry
2006 · University of Würzburg, Germany
M.Sc. – Chemistry (general and computational; minor: Microbiology)
2003 · University of Erlangen-Nürnberg, Germany
B.Sc. – Chemistry
2001 · University of Erlangen-Nürnberg, Germany

Teaching Profile

Courses Taught
2016-2020
PHA7980 Research for Doctoral Dissertation
2016-2021
PHA7979 Advanced Research
2016-2017,2020-2021
PHA6910 Supervised Research
2016-2020
PHA5755 Micro, Immun, Virol
2019-2021
PHA6133 Translational Clinical Pharmacology
2016-2019
PHA5782C Patient Care 2
2018
GMS7979 Advanced Research
2016-2018
PHA6125 Pharmacokinetics and Biopharmaceutics
2017-2018
PHA6935 Selected Topics in Pharmacy
2017
PHA6938 Research Seminar

Contact Details

Phones:
Business:
(407) 313-7010
Emails: